Immix Biopharma, Inc. (IMMX)

NASDAQ: IMMX · USD

$8.10

+0.05 (+0.6%)· Recorded snapshot

Market cap	671.5M
Net income (ttm)	-39.9M
EPS (ttm)	-$0.83
Shares out	82.9M
Volume	1,021,842
Beta	0.24

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -39.9M
EPS (ttm): -$0.83
Market cap: 671.5M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Trzymaj

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-34.2

P25 n/aP50 n/aP75 n/a

ROIC-22.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All IMMX indicators

Market & fundamental data

Available fields

177

Groups with data

Currency

USD

Showing 177 of 177 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001873835
Company name	Immix Biopharma, Inc.
Country	United States
Country code	US
CUSIP number	45258H106
Earnings date	2026-11-10
Earnings time	amc
Employees	21
Employees change	4
Employees growth	23.53%
Enterprise value	$440.4M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2014
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2021-12-16
Is primary listing	Yes
Is SPAC	No
ISIN number	US45258H1068
Last 10-K release date	2026-03-25
Last earnings date	2026-08-07
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$671.5M
Market cap category	Small-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$8.10
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	IMMX
U.S. state	California
Website	https://www.immixbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-10.3%
FCF / EV yield	-8.74%
FCF yield	-5.76%
P/B ratio	2.52x
Price / tangible book value	2.96x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.9M
ROA	-20.52%
ROA (5Y)	-38.68%
ROCE	-18.2%
ROE	-34.18%
ROE (5Y)	-145.84%
ROIC	-22.18%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-591,111
Depreciation and amortization	$331,670
EBIT	$-41.8M
EBITDA	$-41.5M
EPS	$-0.83
FCF per share	$-0.47
Financing cash flow	$261.5M
Free cash flow	$-39.1M
Free cash flow minus SBC	$-41.7M
Income taxes	$33,310
Investing cash flow	$-9.1M
Net cash flow	$213.9M
Net income	$-39.9M
Operating cash flow minus SBC	$-41.1M
Operating income	$-41.8M
Stock-based compensation	$2.6M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$3.20
Debt / equity	0
Long-term assets	$5.3M
Long-term liabilities	$890,638
Net cash (debt)	$231.1M
Net cash / market cap	34.08%
Net cash growth	2,081.24%
Net debt / equity	-1.01
Piotroski F-Score	2
Property, plant and equipment	$3.2M
Shareholders' equity	$228.9M
Tangible book value	$228.9M
Tangible book value per share	$3.20
Total assets	$239.1M
Total cash	$232.1M
Total debt	$1M
Total liabilities	$10.2M
WACC	5.57%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$233.8M
Current liabilities	$9.3M
Current ratio	25.13
Net working capital	$-7.5M
Quick ratio	24.95
Working capital	$224.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-61.22%
Dividend yield	0%
Shareholder yield	-61.22%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$10.08
1D price change	0.62%
1M price change	-26.62%
1M total return	-26.62%
1W price change	-9.65%
1W total return	-9.65%
1Y price change	137.46%
1Y return CAGR	137.6%
1Y total return	137.46%
20-day SMA	$8.87
200-day SMA	$9.45
3M price change	-7.36%
3M total return	-7.36%
3Y price change	137.46%
3Y return CAGR	33.4%
3Y total return	137.46%
50-day SMA	$11.23
50-day SMA vs 200-day SMA	50over200
52-week high	$15.10
52-week high date	2026-08-25
52-week low	$2.85
52-week low date	2025-11-06
6M price change	-15.53%
6M total return	-15.53%
All-time high	$15.10
All-time high date	2026-08-25
All-time low	$0.68
All-time low date	2022-11-10
Average true range (ATR)	$0.62
Average volume	1.3M
Beta (1Y)	1.39
Beta (2Y)	1.45
Beta (5Y)	0.24
Change from 52-week high	-46.36%
Change from 52-week low	184.11%
Change from all-time high	-46.69%
Change from all-time low	1,083.82%
Change from open	0.62%
Day's gap	0%
Dollar volume	$8.3M
High price	$8.18
Low price	$7.90
Monthly RSI	54.91
Open price	$8.05
Position in 52-week range	71.43%
Premarket change	1.24%
Premarket close	$8.05
Premarket price	$8.15
Premarket volume	333
Previous close	$8.05
Price vs 150-day SMA	-20.12%
Price vs 20-day SMA	-9.21%
Price vs 200-day SMA	-14.82%
Price vs 50-day SMA	-28.34%
Relative volume	0.78
Return from IPO open	63.6%
Return from IPO price	63.6%
RSI	32.66
Sharpe ratio	1.39
Sharpe ratio (3Y)	0.71
Sortino ratio	2.37
Sortino ratio (3Y)	1.22
Volume	1M
Weekly RSI	42.84
YTD price change	53.92%
YTD total return	53.92%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	67.5M
Float percentage	81.46%
Shares change (QoQ)	15.17%
Shares change (YoY)	61.22%
Shares held by insiders	8.2%
Shares held by institutions	64.51%
Shares outstanding	82.9M
Short % of float	15.39%
Short % of shares	12.53%
Short ratio	6.2 days

Deeper analysis on IMMX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this IMMX report

Is a complete IMMX research report available?

No complete published report is available for Immix Biopharma, Inc. (IMMX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Immix Biopharma, Inc. (IMMX)

Price

Financial snapshot

Fair-value bridge

Latest news · IMMX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All IMMX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on IMMX

Frequently asked questions